
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Dr. Robert E. Schoen presents findings from the α-CORRECT study, highlighting the potential of circulating tumor DNA (ctDNA) as a biomarker for recurrence risk assessment in patients with stage III colorectal cancer.






